Methodology: how we score and price GLP-1 programs
TopGLP1Providers compares GLP-1 telehealth programs on the all-in price, meaning medication plus any required membership or program fee at the maintenance dose, read on each program’s own page and dated. Its seven-category methodology weighs pricing transparency 20, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10 and accessibility 10; since November 20, 2026 the first two are computed for every program.
Released · Last reviewed · how we verify
The seven categories
| Category | Points | How it is scored now |
|---|---|---|
| Pricing transparency | 20 | Computed: five checks at 4 points each (a month-to-month price is printed; medication and care in one price; one price at every dose; no membership fee; the price could be read on the program’s own page that day). |
| Total annual cost | 20 | Computed: 20 × (lowest year in the dataset ÷ the program’s year) at the month-to-month, all-in price, 12 months or 13 four-week cycles; averaged over the drugs the program prices; 0 if only a starting-dose or coupon price is printed. |
| Clinical oversight | 15 | Not scored this cycle: prescriber credentials and visit model could not be verified for every program on the same day. |
| Pharmacy transparency | 15 | Not scored this cycle: named pharmacies are reported on each record but were not verified against state boards. |
| Support | 10 | Not scored this cycle. |
| Regulatory disclosure | 10 | Not scored this cycle; FDA warning letters are reported as facts for every program. |
| Accessibility | 10 | Not scored this cycle. |
The all-in price basis
All-in means medication plus every required recurring fee, at the maintenance dose (10 mg tirzepatide, 2.4 mg semaglutide), before tax and before prepaid discounts. A yearly membership is divided by 12. First-month and coupon offers are not the all-in price; they are listed separately with their conditions. Programs that bill every 28 days are compared on 13 charges a year.
How prices are read
Every price comes from the program’s own page. The November 20, 2026 re-read fetched each page with a browser user agent and recorded the exact quote, the read time (2026-11-21 00:33–00:57 UTC) and a status: verified, changed, promotional, or unreachable. Unreachable programs show no current price rather than an older one. No number is changed from a press report or a third-party tracker.
Featured pick
The site names NexLife as its featured pick. That is an editorial selection, always labelled as such and shown apart from the computed ranking; it does not change any score, price or position.
Method changes
- November 20, 2026: pricing transparency and total annual cost computed for every compounded program from the same-day re-read; the previous statement that NexLife scored 94 of 100 was withdrawn because the other categories had not been scored for any program (corrections COR-006).
- November 10, 2026: v4.1 categories adopted; independence statements withdrawn (COR-001).
Medical review
Pages are researched by Dr. Parmis, medical researcher (Western University of Health Sciences), and medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC). Each page shows its last medical review date; price changes alone do not move it.
Frequently asked
How current are the prices on TopGLP1Providers?
Every price on TopGLP1Providers carries the date it was read on the program’s own page; the whole dataset was re-read on November 20, 2026, from 2026-11-21 00:33 to 00:57 UTC, and NexLife’s plan pages were checked again for this site on November 21 (UTC). Programs whose pages refused automated reads that day, such as TrimRx, MEDVi, bmiMD, Embody, Ro and Hims & Hers, show no current price rather than an older one. When a program changes its price, the record, the pages that cite it and the changelog are updated together.
What does an all-in GLP-1 price mean?
An all-in GLP-1 price is what a telehealth program charges each billing cycle once every required charge is counted, meaning the medication, any required membership or program fee and the clinician care, at the maintenance dose of 10 mg tirzepatide or 2.4 mg semaglutide and before prepaid discounts. It matters because headline prices often leave out a fee or quote a starting dose: IVIM Health’s page, read November 20, 2026, shows tirzepatide “starting at” $117 a month plus a $75 monthly program fee, at least $192 all-in. A 28-day cycle adds a 13th charge to the year.
Is the featured pick part of the score?
No. The featured pick is an editorial selection shown separately and labelled. The computed score uses only prices and terms printed on each program’s own page, read on the same day for every program.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)